SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Aripiprazole (1,1,2,2,3,3,4,4-d_8)

Cat. No.: HY-14546S1

CAS No.: 1089115-04-7

Molecular Formula: $C_{23}H_{19}D_8Cl_2N_3O_2$

Molecular Weight: 456.43

Target: 5-HT Receptor; Isotope-Labeled Compounds

Pathway: GPCR/G Protein; Neuronal Signaling; Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMF : ≥ 30 mg/mL (65.73 mM)
DMF : ≥ 30 mg/mL (65.73 mM)
DMSO : ≥ 25 mg/mL (54.77 mM)
DMSO : ≥ 25 mg/mL (54.77 mM)
Ethanol : ≥ 1 mg/mL (2.19 mM)
Ethanol : ≥ 1 mg/mL (2.19 mM)
DMF:PBS (pH 7.2) (1:1) : ≥ 0.12 mg/mL (0.26 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1909 mL	10.9546 mL	21.9092 mL
	5 mM	0.4382 mL	2.1909 mL	4.3818 mL
	10 mM	0.2191 mL	1.0955 mL	2.1909 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Aripiprazole (1,1,2,2,3,3,4,4-d_8) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM[1][2].

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Neurosci. 2021 Dec 9.
- Chemosphere. 2019 Jun;225:378-387.
- Acta Pharmacol Sin. 2021 May 11.
- Int J Pharmaceut. 2020 Jun 15;583:119361.
- Int J Mol Sci. 2024 Jan 14, 25(2), 1035.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Stip E, Tourjman V. et al. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32 Suppl 1:S3-20.

[3]. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.

[4]. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.

[5]. Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T.Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T.Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.Biopharm Drug Dispos. 2012 Jul 27. doi: 10.1002/bdd.1801.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA